Cornell spinout Lexeo Therapeutics has added $100m to its coffers thanks to a series B round co-led by D1 Capital Partners and Eventide Asset Management.

Dundee spinout Exscientia has filed for an offering that would provide exits for SoftBank Vision Fund 2, Novo, BMS, Celgene, Evotec and Pivotal BioVenture Partners.

Amgen, Bristol Myers Briggs and Vertex Pharmaceuticals were among the investors that brought the gene therapy developer’s overall funding to over $164m.

The gene therapy developer secured backing from Lundbeck and Alexandria Real Estate Equities in a series B round that will support the advancement of its clinical pipeline.

Eli Lilly and Alexandria Real Estate Equities are among the investors in a round that took the protein drug developer’s total funding to over $150m.

Dundee spinout Exscientia is continuing a busy fundraising year with a filing for an IPO in the US and a $35m concurrent private placement.

The Ohara Pharmaceutical-backed small-molecule therapy developer has secured $11.8m from new and returning investors.

Toray Engineering has returned to back a $27.3m round for the surgical robot developer, investing alongside Dai-ichi Life and Medipal Innovation.

Myeg returned for augmented reality technology developer HiScene's $41.6m series C-plus round while celiac disease drug developer Calypso Biotech hiked a corporate-backed round to over $33m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.